The same year, brentuximab vedotin was approved in combination with chemotherapy for adult patients with untreated systemic ALCL or another CD30-positive PTCL, based on the ECHELON-2 phase 3 trial (NCT01777152) [78, 79]. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.